ClinicalTrials.gg
Active, not recruitingNCT04663347EPCORE™ NHL-2Updated Nov 3, 2026

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

A Phase 1/2 interventional study of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone and rituximab and lenalidomide in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma, sponsored by Genmab. Active, not recruiting at 57 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Genmab · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
543
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse — 16 open to participants now, 23 under way, 3 of them phase 3. epcoritamab · Lymphoma, Large B-Cell, Diffuse.

Enrollment
Largest of 24
543 · median 41
Started
2020
with 1 other
Phase 1/2
3 of 24
1 open now
Primary completion
2027-09
later than 5 of 22 live
Registered
2nd of 24
by date
Lead sponsor
8 of 24
Genmab

Among the 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse, this one has the largest enrollment, is one of 2 that started in 2020, is one of 3 in phase 1/2, reaches primary completion later than 5 of the 22 other live ones, and was the 2nd registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

16 of the 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse are open now, in 5 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About epcoritamab

epcoritamab: first FDA approval 2023 (EPKINLY), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

The purpose of this trial is to measure the safety and effectiveness of epcoritamab (EPKINLY™), either by itself or together with other therapies, when treating participants with B-cell non-Hodgkin Lymphoma (B-NHL). The aim of the first part of the trial is to identify the most appropriate dose of epcoritamab, and the aim of the second part of the trial is to assess the selected epcoritamab dose in a larger group of participants with B-NHL. All participants in this trial will receive either epcoritamab alone, or epcoritamab combined with another standard treatment regimen, with a total of 10 different treatment arms being studied.

Trial details include:

  • The treatment duration for each participant depends upon which arm of treatment they are assigned to.
  • The visit frequency for each participant depends upon which arm of treatment they are assigned to, but will be weekly to start for all participants, then will decrease to either: every 2 weeks, or every 3 weeks, or every 4 weeks, or every 8 weeks.
  • All participants will receive active drug; no one will be given placebo.

Participants who receive treatment with epcoritamab will have it injected right under the skin. Participants will receive a different regimen of epcoritamab depending upon which arm of treatment they are assigned.

Participants who receive standard treatments will have intravenous (IV) infusions and/or oral administration of those treatments. Participants will receive a different standard treatment regimen depending upon which arm of treatment they are assigned.

Read the detailed description

A Phase 1b/2, open-label, multinational, interventional trial to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics/biomarkers, immunogenicity, and preliminary efficacy of epcoritamab in combination with other standard of care (SOC) agents in participants with B-NHL.

All participants in the trial will receive epcoritamab, as monotherapy or in combination. The following regimens will be investigated:

  • Arm 1: epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in participants with previously untreated diffuse large B-cell lymphoma (DLBCL)
  • Arm 2: epcoritamab + rituximab and lenalidomide (R2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL)
  • Arm 3: epcoritamab + rituximab and bendamustine (BR) in participants with previously untreated FL
  • Arm 4: epcoritamab + rituximab, cytarabine, dexamethasone, and oxaliplatin/ carboplatin (R-DHAX/C) in participants with R/R DLBCL eligible for autologous stem cell transplant (ASCT)
  • Arm 5: epcoritamab + gemcitabine and oxaliplatin (GemOx) in participants with R/R DLBCL ineligible for ASCT due to age, performance status (PS), or comorbidity
  • Arm 6: epcoritamab + R2 in participants with previously untreated FL
  • Arm 7: epcoritamab maintenance in participants with FL who achieve a complete response (CR) or a partial response (PR) following first or second line SOC treatment
  • Arm 8: epcoritamab + reduced dose of R-CHOP (R mini-CHOP) in participants with previously untreated DLBCL who are ineligible to receive full-dose anthracycline
  • Arm 9: epcoritamab + lenalidomide for second-line treatment in participants with R/R FL who progressed within 24 months of initiation of first-line anti-CD20-containing immunochemotherapy
  • Arm 10: epcoritamab + rituximab, ifosfamide, carboplatin, and etoposide phosphate (R-ICE) in participants with R/R DLBCL eligible for ASCT

The trial consists of two parts: Part 1 ('Dose Escalation') and Part 2 ('Dose Expansion'). The primary objective of Part 1 is safety, and it includes Arm 1-5 and Arm 10. Part 2 includes all 10 arms (Arm 1-10) and the primary goal of all arms, except Arm 7, is preliminary efficacy. For Arm 7, the primary goal is safety. Participants in Arm 1-5 and Arm 10 can only participate in either Part 1 or Part 2. Dose Limiting Toxicities (DLTs) will be assessed in Part 1 and for a selected number of participants in Arm 8 during a 28-day period (safety run-in). The arms are conducted in parallel.

03

Conditions studied

  • Diffuse Large B-Cell Lymphoma
  • Follicular Lymphoma

Keywords

  • DuoBody®
  • monoclonal antibodies
  • anti-CD3
  • anti-CD20
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  1. defined as ≥1 measurable nodal lesion (long axis >1.5 cm and short axis >1.0 cm) or ≥1 measurable extra-nodal lesion (long axis >1.0 cm) on computed tomography (CT) or magnetic resonance imaging (MRI). Applies to all arms except arm 7.
  2. (ECOG) PS score of 0, 1 or 2
  3. Acceptable organ function at screening
  4. CD20-positive non-Hodgkin lymphoma (NHL) at most recent representative tumor
  5. If of participant must practicing a highly effective method of
  6. A man who is sexually active with a woman of childbearing potential must agree to use a barrier method of birth control

Arm 1:

  • Newly diagnosed DLBCL
  • DLBCL, not otherwise specified (NOS)
  • "Double-hit" or "triple-hit" DLBCL
  • FL Grade 3B

Arm 2: R/R FL

Arm 3: Newly diagnosed, previously untreated FL grade 1-3A

Arm 4:

  • Documented R/R DLBCL and eligible for HDT-
  • DLBCL, NOS
  • "Double-hit" or "triple-hit" DLBCL
  • FL Grade 3B

Arm 5:

  • Documented R/R DLBCL and ineligible for HDT-ASCT
  • DLBCL, NOS
  • "Double-hit" or "triple-hit" DLBCL
  • FL Grade 3B

Arm 6: Newly diagnosed, previously untreated FL grade 1-3A

Arm 7:

  • FL Grade 1-3A
  • If PR or CR per Lugano criteria following or second-line treatment with SOC regimen, and last dose of SOC within 6 months prior to enrollment.

Arm 8:

  • Newly diagnosed DLBCL who are not fit to receive full-dose anthracycline
  • T-cell/histiocyte rich DLBCL
  • "Double-hit" or "triple-hit" DLBCL
  • FL Grade 3B

Arm 9:

  • R/R FL
  • Progressed within 24 months of initiating first-line treatment

Arm 10:

  • Documented R/R DLBCL and eligible for HDT-ASCT
  • DLBCL, NOS
  • "Double-hit" or "triple-hit" DLBCL
  • FL Grade 3B

Key Exclusion Criteria

  1. Chemotherapy, radiation therapy, or major surgery within 4 weeks prior to the first dose of epcoritamab
  2. Any prior treatment with a bispecific antibody targeting CD3 and CD20.
  3. Treatment with CAR-T therapy within 100 days prior to first dose of epcoritamab
  4. cardiovascular disease
  5. Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results
  6. CNS lymphoma or known CNS involvement by lymphoma at screening as confirmed by MRI/CT scan of the brain and, if clinically indicated, by lumbar puncture
  7. Positive tests for virus or virus indicating acute or chronic infection
  8. Known history of seropositivity of (HIV)
  9. Active tuberculosis or history of completed treatment for active tuberculosis within the past 12 months
  10. Neuropathy > grade 1
  11. Receiving immunostimulatory agent
  12. Prior allogeneic HSCT
  13. Current seizure disorder requiring anti-epileptic therapy

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
543 participants (actual)

Study arms

  • Experimental
    Arm 1 - Epcoritamab + R-CHOP

    In participants with previously untreated DLBCL.

    Drug: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone · Biological: Epcoritamab

  • Experimental
    Arm 2 - Epcoritamab + R2

    In participants with R/R FL.

    Biological: Epcoritamab · Drug: Rituximab and Lenalidomide

  • Experimental
    Arm 3 - Epcoritamab + BR

    In participants with previously untreated FL.

    Drug: rituximab and bendamustine · Biological: Epcoritamab

  • Experimental
    Arm 4 - Epcoritamab + R-DHAX/C

    In participants with R/R DLBCL eligible for ASCT.

    Drug: rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin · Biological: Epcoritamab

  • Experimental
    Arm 5 - Epcoritamab + GemOx

    In participants with R/R DLBCL ineligible ASCT.

    Drug: gemcitabine and oxaliplatin · Biological: Epcoritamab

  • Experimental
    Arm 6 - Epcoritamab + R2

    In participants with previously untreated FL.

    Drug: rituximab and lenalidomide · Biological: Epcoritamab

  • Experimental
    Arm 7 - Epcoritamab maintenance

    In participants with FL who achieved a CR or PR after receiving SOC treatment in 1L or 2L.

    Biological: Epcoritamab

  • Experimental
    Arm 8 - Epcoritamab + R mini-CHOP

    In participants with previously untreated DLBCL who are ineligible to receive full-dose anthracycline.

    Drug: rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone · Biological: Epcoritamab

  • Experimental
    Arm 9 - Epcoritamab + Lenalidomide

    In participants with R/R FL who progressed within 24 months of initiation of first-line anti-CD20-containing immunochemotherapy.

    Drug: Lenalidomide · Biological: Epcoritamab

  • Experimental
    Arm 10 - Epcoritamab + R-ICE

    In participants with R/R DLBCL eligible for ASCT.

    Drug: rituximab, ifosfamide, carboplatin, and etoposide phosphate · Biological: Epcoritamab

Interventions

  • Drugrituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone

    6 cycles (21-day cycles)

    Also known as: R-CHOP

  • Drugrituximab and lenalidomide

    Drug pages: Rituximab · Lenalidomide

    rituximab 6 cycles and lenalidomide 12 cycles (28-day cycles)

    Also known as: R2

  • Drugrituximab and bendamustine

    Drug pages: Rituximab · Bendamustine

    6 cycles (28-day cycles)

    Also known as: BR

  • Drugrituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin

    3 cycles (21-day cycles)

    Also known as: R-DHAX/C

  • Druggemcitabine and oxaliplatin

    Drug pages: Gemcitabine · Oxaliplatin

    4 cycles (28-day cycles)

    Also known as: GemOx

  • BiologicalEpcoritamab

    Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year.

    Also known as: GEN3013, DuoBody®-CD3xCD20, EPKINLY™

  • Drugrituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone

    6 cycles (21-day cycles)

    Also known as: R mini-CHOP

  • 12 cycles (28-day cycles)

  • Drugrituximab, ifosfamide, carboplatin, and etoposide phosphate

    3 cycles (21-day cycles)

    Also known as: R-ICE

  • BiologicalEpcoritamab

    Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years.

    Also known as: GEN3013, DuoBody®-CD3xCD20, EPKINLY™

  • BiologicalEpcoritamab

    Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years.

    Also known as: GEN3013, DuoBody®-CD3xCD20, EPKINLY™

  • BiologicalEpcoritamab

    Every week in cycle 1 and then every 8 weeks for a total of 2 years.

    Also known as: GEN3013, DuoBody®-CD3xCD20, EPKINLY™

  • BiologicalEpcoritamab

    Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8.

    Also known as: GEN3013, DuoBody®-CD3xCD20, EPKINLY™

  • BiologicalEpcoritamab

    Every week in cycle 1-3 and then every 4 weeks for a total of 2 years.

    Also known as: GEN3013, DuoBody®-CD3xCD20, EPKINLY™

  • BiologicalEpcoritamab

    Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until ASCT or disease progression.

    Also known as: GEN3013, DuoBody®-CD3xCD20, EPKINLY™

  • BiologicalEpcoritamab

    Eligible participants will receive subcutaneous (SC) epcoritamab in 28-day cycles. Fixed-treatment epcoritamab will be administered following a 2-Set Up Dosing regimen in Cycle 1. There will be 2 cohorts, 2a and 2b with different dosing schedules. Cohort 2a will be dosed weekly (QW) in Cycles 1-3, once every 2 weeks (Q2W) in Cycles 4-9, and once every 4 weeks (Q4W) in Cycle 10 and beyond for up to 2 years. In cohort 2b, an alternate dosing schedule for epcoritamab will be explored: epcoritamab administered QW for Cycles 1-2 only, then Q4W in Cycle 3 and beyond for up to 2 years.

    Also known as: GEN3013, DuoBody®-CD3xCD20, EPKINLY™

  • DrugRituximab and Lenalidomide

    Drug pages: Rituximab · Lenalidomide

    Rituximab 375 milligrams per meter squared (mg/m\^2) will be administered intravenously QW in Cycle 1 and Q4W in Cycles 2-5. Lenalidomide 20 mg will be administered orally daily for 21 days for 12 cycles.

    Also known as: R2

  • BiologicalEpcoritamab

    Cycle 1-3 every week, every other week Cycle 4-9 and then Q4W until progression or unacceptable toxicity.

    Also known as: GEN3013, DuoBody®-CD3xCD20, EPKINLY™

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With Dose limiting Toxicities (DLTs)

    DLT events are defined as clinically significant adverse events (AEs) or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications as assessed per Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria version 5.0.

    Time frame: During the first cycle (Cycle length= 28 days) in each cohort

  2. Part 1 and Part 2 (Arms 1-5, 7 and 10): Number of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign. (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: From first dose of drug until either 60 days after last dose, date participant withdraws consent, date participant starts a new systemic anticancer therapy, or date participant dies, whichever occurs first (up to approximately 3 years)

  3. Part 2 (Except Arm 7): Overall Response Rate (ORR)

    ORR is defined as the percentage of participants achieving complete response (CR) or partial response (PR) based on Lugano criteria.

    Time frame: Up to 3 years

Secondary outcomes

  1. Part 1 and 2: Clearance (CL) of Epcoritamab

    Time frame: Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years)

  2. Part 1 and 2: Area Under the Concentration-Time Curve (AUC) of Epcoritamab

    Time frame: Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years)

  3. Part 1 and 2: Maximum (Peak) Plasma Concentration (Cmax) of Epcoritamab

    Time frame: Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years)

  4. Part 1 and 2: Time to Reach Cmax (Tmax) of Epcoritamab

    Time frame: Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years)

  5. Part 1 and 2: Terminal Elimination Half-Life (t 1/2) of Epcoritamab

    Time frame: Predose and postdose at multiple timepoints until treatment discontinuation (up to 3 years)

  6. Part 1 and 2: Number of Immune Cell Populations

    Immune cell populations in peripheral blood and tumor biopsies will be assessed.

    Time frame: Up to 2 years

  7. Part 1 and 2: Percentage of Immune Cell Populations

    Immune cell populations in peripheral blood and tumor biopsies will be assessed.

    Time frame: Up to 2 years

  8. Part 1 and 2: Change From Baseline in Cytokine Levels up to Cycle 3

    Change in cytokine levels in peripheral blood samples will be assessed.

    Time frame: Up to Cycle 3 (cycle length = 21 days for Arms 1, 4, 8 and 10; cycle length = 28 days for Arms 2, 3, 5, 6 and 9; cycle length = 28 days (Cycle 1) and 56 days (Cycles 2, 3) for Arm 7)

  9. Part 1 and 2: Change From Baseline in Circulating Tumor Deoxyribonucleic Acid (DNA) Level up to End of Treatment (up to 2 Years)

    Change in circulating tumor DNA levels will be assessed.

    Time frame: Up to 2 years

  10. Part 1 and 2: Number of Participants With Anti-Drug Antibodies (ADAs) to Epcoritamab

    Time frame: Up to 3 years

  11. Part 1: ORR

    ORR is defined as the percentage of participants achieving CR or PR based on Lugano criteria.

    Time frame: Up to 3 years

  12. Part 1 and 2: Duration of Response (DOR)

    DOR: the time from the first documentation of objective tumor response (CR or PR) to the date of first PD or death, whichever occurs earlier, based on Lugano criteria.

    Time frame: Up to 3 years

  13. Part 1 and 2: Time to Response (TTR)

    TTR is defined as the time from Day 1 of Cycle 1 to first documentation of objective tumor response (CR or PR).

    Time frame: Up to 3 years

  14. Part 1 and 2: Progression Free Survival (PFS)

    PFS is defined as the time from Day 1 of Cycle 1 to first documented PD or death due to any cause, whichever occurs earlier, based on Lugano criteria.

    Time frame: Up to 3 years

  15. Part 1 and 2: Overall Survival (OS)

    OS is defined as the time from the date of first dose, to the date of death due to any cause.

    Time frame: Up to 3 years

  16. Part 1 and 2: Time to Next Anti-lymphoma Therapy (TTNT)

    TTNT is defined as the time from Day 1 of Cycle 1 to first documented administration of subsequent anti-lymphoma therapy.

    Time frame: Up to 3 years

  17. Part 1 and 2: Percentage of Participants With Minimal Residual Disease (MRD) Negativity

    It is defined as the percentage of participants with at least 1 MRD negative result.

    Time frame: Up to 3 years

  18. Part 1 and 2: Duration of minimal residual disease (MRD) negativity

    Time frame: Up to 3 years

  19. Part 2 (Arm 7): Percentage of Participants Who Converted From MRD Positivity to MRD Negativity

    Time frame: Up to 3 years

  20. Part 2 (Except Arm 7): Percentage of Participants with Complete Response (CR) in Arms 1 to 10

    Time frame: Up to 3 years

  21. Part 2 (Arm 7): Percentage of Participants With CR

    It is defined as the percentage of participants who remain in complete remission or converting to complete remission after first trial drug administration.

    Time frame: Week 24, Week 48, and Week 96

  22. Part 1 and 2: Time to Complete Response (TTCR)

    TTCR is defined as the time from first trial drug administration to the date of first documented complete response post-treatment.

    Time frame: Up to 3 years

  23. Part 1 and 2: Duration of Complete Response (DoCR)

    DoCR is defined as the time from the first documentation of CR to the date of PD or death, whichever occurs first based on Lugano criteria.

    Time frame: Up to 3 years

  24. Part 2: Number of Participants with AEs (Except Arm 7)

    An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign. (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: From first dose of drug until either 60 days after last dose, date participant withdraws consent, date participant starts a new systemic anticancer therapy, or date participant dies, whichever occurs first (up to approximately 3 years)

07

Study locations

57 sites
08

References and documents

Publications

  • Falchi L, Vermaat JSP, Brody JD, Leslie L, Offner F, Christensen JH, Nijland M, Belada D, Wahlin BE, Drott K, Gomez Prieto P, Kopeckova K, Garcia-Sancho AM, Mei JP, Altintas I, Risum M, Reilly A, Zou J, Abrisqueta P. Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial. Lancet Haematol. 2026 Sep;13(9):e614-e625. doi: 10.1016/S2352-3026(26)00198-5. PubMed 42660129 ↗
  • Falchi L, Offner F, de Vos S, Brody JD, Morillo D, Linton K, Snauwaert S, Roost Clausen M, Karimi YH, Thieblemont C, Vitolo U, Leslie LA, Narkhede MS, Cordoba R, Oki T, Wielgos-Bonvallet M, Khoshdeli M, Hao Y, Archer K, Risum M, Belada D. Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial. Blood. 2026 Aug 11:blood.2026033839. doi: 10.1182/blood.2026033839. Online ahead of print. PubMed 42622258 ↗
  • Abrisqueta P, Karimi YH, Morillo D, Cordoba R, Phillips T, De Vos S, Nijland M, Offner F, Andersson PO, Brody J, Cheah CY, Prieto PG, Hellstrom M, Jorgensen JM, Lewis D, Linton KM, Musuraca G, Wang L, Marek J, Osei-Bonsu K, Risum M, Falchi L. Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial. Haematologica. 2026 Oct 1;111(10):3346-3357. doi: 10.3324/haematol.2025.300086. Epub 2026 Mar 5. PubMed 41784015 ↗
  • Falchi L, Sureda A, Leppa S, Vermaat JSP, Nijland M, Christensen JH, de Vos S, Holte H, Merryman RW, Lugtenburg PJ, Abrisqueta P, Linton KM, Sunkersett G, Hoehn D, Rana A, Abbas A, Marek J, Hao Y, Steele AJ, Morehouse C, Hutchings M, Belada D. Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma. Blood. 2025 Nov 27;146(22):2629-2640. doi: 10.1182/blood.2025029909. PubMed 40920572 ↗
  • Brody JD, Jorgensen J, Belada D, Costello R, Trneny M, Vitolo U, Lewis DJ, Karimi YH, Sureda A, Andre M, Wahlin BE, Lugtenburg PJ, Jiang T, Karagoz K, Steele AJ, Abbas A, Wang L, Risum M, Cordoba R. Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial. Blood. 2025 Apr 10;145(15):1621-1631. doi: 10.1182/blood.2024026830. PubMed 39792928 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Sep 2027, 82 months after the start.

Of 51 industry-sponsored phase 1/2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 99. This study's planned 82 months is close to that.

Counting every sponsor, half of 108 studies reached it within 70 months; a quarter within 50 and three quarters within 98.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2020
First posted
Dec 11, 2020
StartActual
Nov 3, 2020
Primary completionEst.
Sep 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41784015 ↗
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41784015 ↗
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04663347
Lead sponsor
Genmab
Collaborators
AbbVie
Responsible party
Sponsor
First posted
Dec 11, 2020
Start date
Nov 3, 2020
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Nov 3, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epcoritamab

Start the discussion